AstraZeneca (AZN) Denied Request for Preliminary Injunction in Generic Quetiapine/FDA Suit
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) reports that on March 23, 2012 the US District Court for the District of Columbia issued an opinion and order in AstraZeneca’s lawsuit against the US Food and Drug Administration (FDA) regarding final marketing approval of generic quetiapine. The Court denied the Company’s request for a preliminary injunction and dismissed the lawsuit without prejudice.
Notwithstanding the Court’s decision, the Company continues to believe strongly in the merits of its position and is evaluating its options.
Notwithstanding the Court’s decision, the Company continues to believe strongly in the merits of its position and is evaluating its options.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Nu Skin EVP of global sales takes medical leave
- Gray Media closes $750M note offering to refinance higher-rate debt
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
